Skip to main content
. Author manuscript; available in PMC: 2016 Oct 25.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2016 May 28;96(2):362–371. doi: 10.1016/j.ijrobp.2016.05.026

Table 1. Patient characteristics.

Characteristic Neck dissected (n=99) Neck observed (n=193) P
Assigned treatment .80*
 SFX + cisplatin 53 (53.5) 99 (51.3)
 AFX-C + cisplatin 46 (46.5) 94 (48.7)
Age (y) .12
 Median (range) 55 (37-71) 55 (31-82)
Sex .02*
 Male 90 (90.9) 154 (79.8)
 Female 9 (9.1) 39 (20.2)
Race .72*
 White 84 (84.8) 167 (86.5)
 Non-white 15 (15.2) 26 (13.5)
Zubrod performance status .80*
 0 64 (64.6) 128 (66.3)
 1 35 (35.4) 65 (33.7)
Smoking history: pack-years (n=81) (n=160) .96
 Median (range) 20 (0-152) 20 (0-92.5)
Primary site 1.00*
 Oropharynx, NOS 15 (15.2) 17 (8.8)
 Faucial arch 0 (0.0) 1 (0.5)
 Tonsillar fossa, tonsil 44 (44.4) 81 (42.0)
 Base of tongue 37 (37.4) 78 (40.4)
 Pharyngeal oropharynx 2 (2.0) 8 (4.1)
 Soft palate 1 (1.0) 8 (4.1)
p16 status .79*
 p16 positive 69 (69.7) 130 (67.4)
 p16 negative 30 (30.3) 63 (32.6)
T stage .14
 T2 40 (40.4) 54 (28.0)
 T3 31 (31.3) 81 (42.0)
 T4 28 (28.3) 58 (30.1)
N stage .01
 N1 4 (4.0) 42 (21.8)
 N2a 21 (21.2) 15 (7.8)
 N2b 33 (33.3) 72 (37.3)
 N2c 21 (21.2) 53 (27.5)
 N3 20 (20.2) 11 (5.7)
Primary disease status after chemoradiotherapy .03§
 Absent 74 (74.7) 145 (75.1)
 Present 19 (19.2) 21 (10.9)
 Unknown 6 (6.1) 27 (14.0)
Neck disease status after chemoradiotherapy <.001§
 Absent 35 (35.4) 136 (70.5)
 Present 54 (54.5) 33 (17.1)
 Unknown 10 (10.1) 24 (12.4)

Abbreviations: AFX-C = accelerated fractionation with concomitant boost radiation therapy; NOS = not otherwise specified; SFX = standard fractionation radiation therapy.

Values are number (percentage) unless otherwise noted.

*

Fisher exact test. Primary site is tested as tonsil or base of tongue versus others.

Wilcoxon rank-sum test.

A pack-year is defined as the equivalent of smoking one pack of cigarettes a day for 1 year.

§

Chi-squared test.